PPLPHARMA

Piramal Pharma Share Price

 

Stock touched 52W low

 

Invest in Piramal Pharma with 3.11X leverage

Invest with MTF

Performance

  • Low
  • ₹177
  • High
  • ₹182
  • 52 Week Low
  • ₹177
  • 52 Week High
  • ₹279
  • Open Price₹182
  • Previous Close₹181
  • Volume2,246,077

Investment Returns

  • Over 1 Month -10.26%
  • Over 3 Month -10.37%
  • Over 6 Month -13.57%
  • Over 1 Year -34.4%

Smart Investing Starts Here Start SIP with Piramal Pharma for Steady Growth!

Invest Now

Piramal Pharma Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.

  • P/E Ratio
  • -1007
  • PEG Ratio
  • 6.6
  • Market Cap Cr
  • 23,907
  • P/B Ratio
  • Average True Range
  • 4.4
  • EPS
  • 0
  • Dividend Yield
  • 0.1
  • MACD Signal
  • -3.24
  • RSI
  • 28.88
  • MFI
  • 21.63

Piramal Pharma Financials

Piramal Pharma Technicals

EMA & SMA

Current Price
₹179.85
-1 (-0.55%)
pointer
  • Bearish Moving Average 16
  • Bullish Moving Average 0
  • 20 Day
  • ₹187.88
  • 50 Day
  • ₹192.51
  • 100 Day
  • ₹196.33
  • 200 Day
  • ₹200.22

Resistance and Support

179.64 Pivot Speed
  • R3 186.01
  • R2 183.82
  • R1 181.83
  • S1 177.65
  • S2 175.46
  • S3 173.47

Ratings

Master Rating

EPS Strenth

Price Strength

Buyer Demand

Group Rank

Piramal Pharma Ltd. provides pharmaceutical solutions, including contract manufacturing, active pharmaceutical ingredients (APIs), and consumer healthcare products. It serves global markets, offering high-quality healthcare products to pharmaceutical companies and end consumers.

Piramal Pharma has an operating revenue of Rs. 8,935.72 Cr. on a trailing 12-month basis. An annual revenue growth of 11% is good, Pre-tax margin of 4% needs improvement, ROE of 1% is fair but needs improvement. The company has a reasonable debt to equity of 40%, which signals a healthy balance sheet. The stock from a technical standpoint is trading below to its key moving averages. It needs to take out these levels and stay above it to make any meaningful move. From an O'Neil Methodology perspective, the stock has an EPS Rank of 14 which is a POOR score indicating inconsistency in earnings, a RS Rating of 34 which is POOR indicating the underperformance as compared to other stocks, Buyer Demand at B- which is evident from recent demand for the stock, Group Rank of 66 indicates it belongs to a poor industry group of Medical-Diversified and a Master Score of D is close to being the worst. Institutional holding has gone up in the last reported quarter is a positive sign. Overall, the stock has poor technical strength and poor fundamentals, there are superior stocks in the current market environment.

Disclaimer: This stock analysis report is algorithmically generated for informational purposes only and should not be considered as a buy or sell recommendation.

View More

Piramal Pharma Corporate Actions - Bonus, Splits, Dividends

Date Purpose Remarks
2025-11-05 Quarterly Results
2025-07-28 Quarterly Results
2025-05-14 Audited Results & Final Dividend
2025-01-28 Quarterly Results
2024-10-23 Quarterly Results
Date Purpose Remarks
2025-07-16 FINAL Rs.0.14 per share(1.4%)Final Dividend
2024-07-12 FINAL Rs.0.11 per share(1.1%)Final Dividend
View Piramal Pharma Dividend History Arrow

Piramal Pharma F&O

Piramal Pharma Shareholding Pattern

34.86%
13.11%
1.49%
12.32%
0%
14.11%
24.11%

Piramal Pharma FAQs

Piramal Pharma share price is ₹179 As on 06 December, 2025 | 10:20

The Market Cap of Piramal Pharma is ₹23906.5 Cr As on 06 December, 2025 | 10:20

The P/E ratio of Piramal Pharma is -1007 As on 06 December, 2025 | 10:20

The PB ratio of Piramal Pharma is 3 As on 06 December, 2025 | 10:20

Open Free Demat Account

Be a part of 5paisa community - The first listed discount broker of India.

+91

By proceeding, you agree to all T&C*

footer_form

Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.

Q2FY23